Studio esplorativo della piattaforma di fase II sui regimi di priming Volrustomig (eVOLVE-01)
Uno studio di Fase II, in aperto, per valutare la sicurezza, la tollerabilità, la farmacocinetica, l'immunogenicità e l'attività antitumorale dei regimi di priming di Volrustomig in combinazione con altri agenti antitumorali in partecipanti con tumori solidi (eVOLVE-01)
Purpose of this study is to assess the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of volrustomig in combination with other anticancer drugs in participants with specified solid tumors.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
This Phase II, platform, open-label, multicenter study will evaluate the efficacy, safety, and tolerability of volrustomig in combination with anticancer drugs in various solid tumor types.
This platform study currently includes 2 substudies:
Substudy 1: metastatic non-small cell lung cancer (mNSCLC) (non-squamous [NSQ]). Participants will be randomized in two treatment arms: Arm 1A and Arm 1B.
Substudy 2: mNSCLC (squamous [SQ] or NSQ). Participants will enroll to the Arm 2A only.
All arms will test a volrustomig dosing in combination with chemotherapy.
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
-
Beijing, Cina, 100730
- Research Site
-
Hangzhou, Cina, 310014
- Research Site
-
Jinan, Cina, 250013
- Research Site
-
Yantai, Cina, 264000
- Research Site
-
Zhengzhou, Cina, 450000
- Research Site
-
-
-
-
-
Seongnam, Corea del Sud, 13620
- Research Site
-
Seoul, Corea del Sud, 03722
- Research Site
-
Suwon, Corea del Sud, 16247
- Research Site
-
-
-
-
-
Bois-Guillaume, Francia, 76031
- Research Site
-
Caen, Francia, 14076
- Research Site
-
Dijon, Francia, 21079
- Research Site
-
Montpellier, Francia, 34070
- Research Site
-
-
-
-
-
Batumi, Georgia, 6010
- Research Site
-
Tbilisi, Georgia, 0144
- Research Site
-
Tbilisi, Georgia, 0112
- Research Site
-
Tbilisi, Georgia, '0159
- Research Site
-
Tbilisi, Georgia, 186
- Research Site
-
Tbilisi, Georgia, 0114
- Research Site
-
-
-
-
-
Athens, Grecia, 115 27
- Research Site
-
Athens, Grecia, 12462
- Research Site
-
Elaiones, Grecia, 546 23
- Research Site
-
Piraeus, Grecia, 185 47
- Research Site
-
Thessaloniki, Grecia, 57001
- Research Site
-
-
-
-
-
Genoa, Italia, 16132
- Research Site
-
Meldola, Italia, 47014
- Research Site
-
Milan, Italia, 20133
- Research Site
-
Naples, Italia, 80131
- Research Site
-
Orbassano, Italia, 10043
- Research Site
-
Perugia, Italia, 06132
- Research Site
-
Rozzano, Italia, 20089
- Research Site
-
Udine, Italia, 33100
- Research Site
-
Verona, Italia, 37134
- Research Site
-
-
-
-
-
Kuala Lumpur, Malaysia, 59100
- Research Site
-
Kuching, Malaysia, 93586
- Research Site
-
Perai, Malaysia, 13700
- Research Site
-
-
-
-
-
Lisbon, Portogallo, 1649-035
- Research Site
-
Lisbon, Portogallo, 1169-050
- Research Site
-
Lisbon, Portogallo, 1400-038
- Research Site
-
Porto, Portogallo, 4099-001
- Research Site
-
-
-
-
-
Cluj-Napoca, Romania, 400641
- Research Site
-
Craiova, Romania, 200542
- Research Site
-
Floreşti, Romania, 407280
- Research Site
-
-
-
-
-
Belgrade, Serbia, 11000
- Research Site
-
-
-
-
-
A Coruña, Spagna, 15009
- Research Site
-
Alcorcón, Spagna, 28922
- Research Site
-
Barcelona, Spagna, 08041
- Research Site
-
Madrid, Spagna, 28041
- Research Site
-
Málaga, Spagna, 29004
- Research Site
-
Pamplona, Spagna, 31008
- Research Site
-
Santander, Spagna, 39008
- Research Site
-
Santiago de Compostela, Spagna, 15706
- Research Site
-
Valencia, Spagna, 46026
- Research Site
-
Valencia, Spagna, 46015
- Research Site
-
-
-
-
California
-
Los Angeles, California, Stati Uniti, 90067
- Research Site
-
-
North Carolina
-
Chapel Hill, North Carolina, Stati Uniti, 27514
- Research Site
-
-
-
-
-
Geneva, Svizzera, 1205
- Research Site
-
Lausanne, Svizzera, 1011
- Research Site
-
Winterthur, Svizzera, 8401
- Research Site
-
Zurich, Svizzera, 8091
- Research Site
-
-
-
-
-
Changhua, Taiwan, 50006
- Research Site
-
New Taipei City, Taiwan, 23561
- Research Site
-
Taipei, Taiwan, 106
- Research Site
-
Taipei, Taiwan, 110
- Research Site
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Key Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 with no deterioration.
- Life expectancy greater than or equal to (>=) 12 weeks.
- Adequate organ and bone marrow function.
- Body weight greater than (>) 35 kilograms (kg) at screening and at randomization.
- Histologically or cytologically documented NSQ NSCLC in substudy 1 and SQ or NSQ mNSCLC in substudy 2.
- Absence of sensitizing epidermal growth factor receptor (EGFR) mutations.
- Absence of documented tumor genomic alteration results from tests conducted as part of standard local practice in any other actionable driver oncogenes for which there are locally approved targeted 1L therapies.
- At least one measurable lesion not previously irradiated that can be accurately measured at baseline as >= 10 millimeter (mm) in the longest diameter.
Key Exclusion Criteria:
- Spinal cord compression.
- History of primary active immunodeficiency.
- Active or prior documented autoimmune or inflammatory disorders.
- Mixed small-cell lung cancer and NSCLC histology or sarcomatoid variant.
- Brain metastases unless asymptomatic, stable, and not requiring steroids for at least 14 days prior to start of study intervention. A minimum of 2 weeks must have elapsed between the end of radiation therapy and study enrollment.
- Prior chemotherapy or any other systemic therapy for Stage IV NSCLC. Participants who have received prior platinum-containing adjuvant, neoadjuvant, or definitive chemoradiation for local disease are eligible, provided that progression has occurred greater (>) 12 months from end of last therapy.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Substudy 1: Arm 1A: Volrustomig dose regimen 1 + Carboplatin and Pemetrexed
Volrustomig priming dose followed by volrustomig dosing regimen 1 in combination with carboplatin and pemetrexed. |
Participants will receive volrustomig via intravenous (IV) infusion.
Altri nomi:
Participants will receive carboplatin via IV infusion. Participants will receive pemetrexed via IV infusion. |
|
Sperimentale: Substudy 1: Arm 1B: Volrustomig dose regimen 2 + Carboplatin and Pemetrexed
Volrustomig priming dose followed by volrustomig dosing regimen 2 in combination with carboplatin and pemetrexed. |
Participants will receive volrustomig via intravenous (IV) infusion.
Altri nomi:
Participants will receive carboplatin via IV infusion. Participants will receive pemetrexed via IV infusion. |
|
Sperimentale: Substudy 2: Arm 2A: Volrustomig dose regimen 2 +Ramucirumab + Carboplatin + Pemetrexed or Paclitaxel
Volrustomig priming dose followed by volrustomig dosing regimen 2 in combination with ramucirumab and histology-specific chemotherapy (carboplatin+ either pemetrexed or paclitaxel). |
Participants will receive volrustomig via intravenous (IV) infusion.
Altri nomi:
Participants will receive carboplatin via IV infusion. Participants will receive pemetrexed via IV infusion. Participants will receive ramucirumab via IV infusion. Participants will receive paclitaxel via IV infusion. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Lasso di tempo: From screening (Days -28 to Day -1) up to 2 year 10 months
|
The safety and tolerability of volrustomig in combination with other anticancer drugs in participants with specified solid tumors will be assessed. |
From screening (Days -28 to Day -1) up to 2 year 10 months
|
|
Confirmed Objective Response rate (ORR)
Lasso di tempo: Up to 2 year 10 months
|
ORR is defined as the percentage of participants who have a confirmed complete response (CR) or confirmed partial response (PR), as per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1). |
Up to 2 year 10 months
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Disease Control Rate (DCR)
Lasso di tempo: Up to 2 year 10 months
|
DCR is defined as the percentage of participants who have a CR or PR or who have stable disease (SD) after the date of randomization or first dose. |
Up to 2 year 10 months
|
|
Duration of Response (DOR)
Lasso di tempo: Up to 2 year 10 months
|
DOR is defined as the time from the date of first documented response until the date of documented progression or death due to any cause (in the absence of progression). |
Up to 2 year 10 months
|
|
Progression Free Survival (PFS)
Lasso di tempo: Up to 2 year 10 months
|
PFS is defined as the time from randomization or first dose until radiological progression or death due to any cause (in the absence of progression). |
Up to 2 year 10 months
|
|
Overall Survival (OS)
Lasso di tempo: Up to 2 year 10 months
|
OS is defined as the time from randomization or first dose until the date of death due to any cause. |
Up to 2 year 10 months
|
|
Serum Concentration of Volrustomig
Lasso di tempo: Up to 2 year 10 months
|
The serum concentrations volrustomig alone and when used in combination with other anticancer agents in participants with pre-specified solid tumors will be assessed. |
Up to 2 year 10 months
|
|
Trough concentration (Ctrough)
Lasso di tempo: Up to 2 year 10 months
|
The trough concentrations volrustomig alone and when used in combination with other anticancer agents in participants with pre-specified solid tumors will be assessed. |
Up to 2 year 10 months
|
|
Maximum Observed Concentration (Cmax)
Lasso di tempo: Up to 2 year 10 months
|
The serum concentrations volrustomig alone and when used in combination with other anticancer agents in participants with pre-specified solid tumors will be assessed. |
Up to 2 year 10 months
|
|
Area Under the Curve (AUC)
Lasso di tempo: Up to 2 year 10 months
|
The AUC concentrations of volrustomig alone and when used in combination with other anticancer agents in participants with pre-specified solid tumors will be assessed. |
Up to 2 year 10 months
|
|
Number of Participants with Positive Antidrug Antibodies (ADAs)
Lasso di tempo: Up to 2 year 10 months
|
The incidence of ADAs against volrustomig or other anticancer agents in serum will be assessed. |
Up to 2 year 10 months
|
Collaboratori e investigatori
Sponsor
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Neoplasie per sede
- Neoplasie
- Malattie delle vie respiratorie
- Malattie polmonari
- Neoplasie delle vie respiratorie
- Neoplasie toraciche
- Neoplasie polmonari
- Carcinoma, broncogeno
- Neoplasie bronchiali
- Carcinoma, polmone non a piccole cellule
- Aminoacidi, peptidi e proteine
- Proteine
- Prodotti chimici organici
- Composti eterociclici
- Composti eterociclici, 2 anelli
- Composti eterociclici, anello fuso
- Idrocarburi
- Cicloparaffins
- Idrocarburi, aliciclici
- Idrocarburi, ciclici
- Terpeni
- Anticorpi, monoclonali, umanizzati
- Anticorpi, monoclonali
- Anticorpi
- Immunoglobuline
- Immunoproteine
- Proteine del sangue
- Globuline sieriche
- Globuline
- Complessi di coordinamento
- Guanina
- Ipossantine
- Purinoni
- Purine
- Glutammati
- Aminoacidi, acido
- Aminoacidi
- Aminoacidi, dicarbossilico
- Taxoidi
- Ciclodecani
- Diterpenes
- Pemetrexed
- Ramucirumab
- Carboplatino
- Paclitaxel
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- D798KC00001
- 2023-509482-20-00 (Identificatore di registro: CTIS)
- 2023 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Qualified researchers can request access to anonymized individual patient-leveldata from AstraZeneca group of companies sponsored clinical trials via therequest portal Vivli.org. All requests will be evaluated as per the AZ disclosurecommitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure."Yes",indicates that AZ are accepting requests for IPD, but this does not mean allrequests will be approved.
Periodo di condivisione IPD
AstraZeneca will meet or exceed data availability as per the commitment smade to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment athttps://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Criteri di accesso alla condivisione IPD
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure researchenvironmentVivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .